NCT02227212View on ClinicalTrials.gov

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Insulin glargine U300 (new formulation of insulin glargine) HOE901

Pharmaceutical form:solution for injection Route of administration: subcutaneous

Trial Locations (7)

10115

Investigational Site Number 276008, Berlin

14469

Investigational Site Number 276007, Potsdam

22607

Investigational Site Number 276002, Hamburg

45355

Investigational Site Number 276009, Essen

48145

Investigational Site Number 276001, Münster

86150

Investigational Site Number 276011, Augsburg

88239

Investigational Site Number 276004, Wangen

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY